Procyon Stock Performance
| PCYN Stock | USD 0.24 0.01 4.35% |
The company holds a Beta of 0.11, which implies not very significant fluctuations relative to the market. As returns on the market increase, Procyon's returns are expected to increase less than the market. However, during the bear market, the loss of holding Procyon is expected to be smaller as well. Procyon right now holds a risk of 6.81%. Please check Procyon jensen alpha, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Procyon will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Procyon has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Procyon is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 1.2 M | |
| Total Cashflows From Investing Activities | -82.6 K |
Procyon |
Procyon Relative Risk vs. Return Landscape
If you would invest 27.00 in Procyon on October 1, 2024 and sell it today you would lose (3.00) from holding Procyon or give up 11.11% of portfolio value over 90 days. Procyon is currently generating 0.0395% in daily expected returns and assumes 6.8064% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of pink sheets are less volatile than Procyon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Procyon Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Procyon's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Procyon, and traders can use it to determine the average amount a Procyon's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCYN |
Estimated Market Risk
| 6.81 actual daily | 60 60% of assets are less volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Procyon is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Procyon by adding Procyon to a well-diversified portfolio.
Procyon Fundamentals Growth
Procyon Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Procyon, and Procyon fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Procyon Pink Sheet performance.
| Return On Equity | -0.0934 | |||
| Return On Asset | -0.0501 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 1.82 M | |||
| Shares Outstanding | 8.09 M | |||
| Price To Earning | 8.00 X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.40 X | |||
| Revenue | 4.84 M | |||
| EBITDA | (19.2 K) | |||
| Cash And Equivalents | 1.04 M | |||
| Cash Per Share | 0.13 X | |||
| Total Debt | 694.3 K | |||
| Debt To Equity | 0.26 % | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (229.46 K) | |||
| Earnings Per Share | 0.03 X | |||
| Total Asset | 3.8 M | |||
| Retained Earnings | (2.46 M) | |||
| Current Asset | 1.88 M | |||
| Current Liabilities | 842.7 K | |||
About Procyon Performance
By examining Procyon's fundamental ratios, stakeholders can obtain critical insights into Procyon's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Procyon is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 19 people.Things to note about Procyon performance evaluation
Checking the ongoing alerts about Procyon for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Procyon help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Procyon had very high historical volatility over the last 90 days | |
| Procyon has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 4.84 M. Net Loss for the year was (209.79 K) with profit before overhead, payroll, taxes, and interest of 3.49 M. | |
| Procyon currently holds about 1.04 M in cash with (229.46 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Procyon's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Procyon's stock is overvalued or undervalued compared to its peers.
- Examining Procyon's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Procyon's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Procyon's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Procyon's pink sheet. These opinions can provide insight into Procyon's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Procyon Pink Sheet
Procyon financial ratios help investors to determine whether Procyon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Procyon with respect to the benefits of owning Procyon security.